Posted by ABMN Staff on May 14th, 2024
HC Wainwright restated their buy rating on shares of LifeMD (NASDAQ:LFMD – Free Report) in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a $12.00 price target on the stock.
A number...
More of this article »